#1 Clinical Trials Search in Europe

Sunvozertinib

Sunvozertinib is an emerging drug being studied in clinical trials for the treatment of advanced non-small cell lung cancer (NSCLC), particularly in patients with specific genetic mutations. These trials aim to evaluate the safety, efficacy, and potential benefits of Sunvozertinib, either alone or in combination with other treatments, for patients who have limited options or have progressed after previous therapies. The ongoing research focuses on various aspects of the drug’s performance, including its ability to shrink tumors, extend survival, and improve quality of life for patients with this challenging form of lung cancer.

Table of Contents

What is Sunvozertinib?

Sunvozertinib is a new medication being studied for the treatment of non-small cell lung cancer (NSCLC). It is also known by the name DZD9008[2]. Sunvozertinib belongs to a class of drugs called EGFR inhibitors, which target specific genetic mutations found in some lung cancers.

How Does Sunvozertinib Work?

Sunvozertinib works by targeting and blocking specific proteins called epidermal growth factor receptors (EGFR) on cancer cells. Some lung cancers have mutations in the EGFR gene that cause these proteins to be overactive, leading to uncontrolled cancer growth. By blocking these abnormal EGFR proteins, Sunvozertinib can help slow or stop cancer growth[2].

What Conditions Does Sunvozertinib Treat?

Sunvozertinib is being studied primarily for the treatment of non-small cell lung cancer (NSCLC) that has specific genetic mutations. It is being investigated for use in patients with:

  • Advanced or metastatic NSCLC: This means lung cancer that has spread to other parts of the body or cannot be surgically removed[1].
  • EGFR mutations: Specifically, patients whose cancer has mutations in the EGFR gene, including uncommon mutations like EGFR exon 20 insertions[2].
  • HER2 mutations: Some studies are also looking at Sunvozertinib in patients with HER2 gene mutations[2].

How is Sunvozertinib Given?

Sunvozertinib is an oral medication, which means it is taken by mouth. In most clinical trials, it is given as a daily dose. The exact dosage can vary depending on the specific study, but common doses being tested include:

  • 200 mg once daily[1]
  • 300 mg once daily[3]

It’s important to note that the optimal dose is still being determined through clinical trials.

Ongoing Clinical Trials

Several clinical trials are currently underway to study Sunvozertinib. These trials are investigating:

  • Effectiveness as a single agent: Some trials are looking at how well Sunvozertinib works on its own in patients whose cancer has progressed after other treatments[2].
  • Combination with chemotherapy: Other studies are testing Sunvozertinib in combination with standard chemotherapy drugs[1].
  • Combination with other targeted therapies: Some trials are investigating the combination of Sunvozertinib with other cancer drugs like Anlotinib[3][4].
  • First-line treatment: Researchers are exploring whether Sunvozertinib could be used as an initial treatment for some patients with specific genetic mutations[4].
  • Neoadjuvant therapy: One study is looking at using Sunvozertinib before surgery in patients with stage III NSCLC[6].

Potential Side Effects

As Sunvozertinib is still in clinical trials, the full range of potential side effects is not yet known. However, researchers are carefully monitoring for adverse events in all ongoing studies. Common side effects of similar EGFR inhibitor drugs can include skin rash, diarrhea, and fatigue. The clinical trials are designed to assess the safety and tolerability of Sunvozertinib, and this information will be crucial for understanding its side effect profile[2][3].

Future Directions

The research on Sunvozertinib is ongoing, and scientists are exploring several important questions:

  • Effectiveness against specific mutations: Researchers are particularly interested in how well Sunvozertinib works against uncommon EGFR mutations like exon 20 insertions[2].
  • Combination strategies: Studies are investigating whether combining Sunvozertinib with other treatments can improve outcomes for patients[1][3].
  • Use in earlier stages of disease: Some trials are exploring whether Sunvozertinib could be beneficial when used earlier in the course of treatment[4][6].
  • Long-term safety and efficacy: Ongoing and future studies will continue to monitor how well Sunvozertinib works over time and any long-term side effects[2].

As research continues, more information will become available about the effectiveness and safety of Sunvozertinib. Patients interested in learning more about this medication should speak with their healthcare provider about the latest developments and whether it might be an appropriate treatment option for their specific situation.

Aspect Details
Drug Name Sunvozertinib (also known as DZD9008)
Target Condition Advanced Non-Small Cell Lung Cancer (NSCLC) with specific mutations (e.g., EGFR exon 20 insertions)
Administration Oral, typically 200-300 mg once daily
Trial Phases Phase I/II and Phase II studies
Primary Outcomes Objective Response Rate (ORR), Progression-Free Survival (PFS), Safety and Tolerability
Secondary Outcomes Overall Survival (OS), Duration of Response (DoR), Disease Control Rate (DCR)
Combination Therapies Studies with chemotherapy, Anlotinib
Patient Populations Treatment-naive and previously treated NSCLC patients
Evaluation Criteria RECIST v1.1, Independent Review Committee (IRC) assessments
Safety Monitoring Adverse Events (AEs) according to CTCAE criteria

FAQ

  • What is Sunvozertinib? Sunvozertinib is an oral EGFR inhibitor being studied for the treatment of advanced non-small cell lung cancer (NSCLC), particularly in patients with EGFR mutations or HER2 mutations.
  • What types of patients are being studied in Sunvozertinib clinical trials? Clinical trials are focusing on patients with advanced NSCLC who have specific genetic mutations, such as EGFR exon 20 insertions, and those who have progressed after previous treatments like EGFR-TKI therapy or platinum-based chemotherapy.
  • How is Sunvozertinib administered in these trials? Sunvozertinib is typically administered orally, with doses ranging from 200 mg to 300 mg once daily, depending on the specific trial and treatment regimen.
  • What are the main goals of these clinical trials? The main goals include assessing the safety and tolerability of Sunvozertinib, evaluating its anti-tumor efficacy through measures like objective response rate (ORR) and progression-free survival (PFS), and studying its pharmacokinetics (how the drug moves through the body).
  • Are there any combination therapies being studied with Sunvozertinib? Yes, some trials are investigating Sunvozertinib in combination with other treatments, such as chemotherapy or other targeted therapies like Anlotinib, to potentially enhance its effectiveness in treating NSCLC.

Ongoing Clinical Trials on Sunvozertinib

  • Study on the Safety and Effectiveness of Sunvozertinib for Patients with Advanced Non-Small Cell Lung Cancer with EGFR or HER2 Mutations

    Not recruiting

    1 1 1
    Investigated drugs:
    France Italy Spain

  • Study Comparing DZD9008 and Chemotherapy for First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Mutation

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia France Germany Italy +3

Glossary

  • NSCLC: Non-Small Cell Lung Cancer, a type of lung cancer that is the most common form, accounting for about 80-85% of all lung cancers.
  • EGFR: Epidermal Growth Factor Receptor, a protein on cells that helps them grow. Some NSCLC tumors have too much EGFR, which causes them to grow faster.
  • TKI: Tyrosine Kinase Inhibitor, a type of targeted therapy that blocks specific enzymes called tyrosine kinases, which are involved in cancer cell growth.
  • Exon 20 insertion: A specific type of mutation in the EGFR gene that can make some lung cancers grow and spread.
  • ORR: Objective Response Rate, the proportion of patients whose cancer shrinks or disappears after treatment.
  • PFS: Progression-Free Survival, the length of time during and after treatment that a patient lives with the disease without it getting worse.
  • OS: Overall Survival, the length of time from the start of treatment that patients are still alive.
  • Pharmacokinetics: The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • Adverse Events: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.

References

  1. https://clinicaltrials.gov/study/NCT06195189
  2. https://clinicaltrials.gov/study/NCT03974022
  3. https://clinicaltrials.gov/study/NCT06182761
  4. https://clinicaltrials.gov/study/NCT06348927
  5. https://clinicaltrials.gov/study/NCT06355609
  6. https://clinicaltrials.gov/study/NCT06563999